Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Colombia v Novartis: Do Big Prices Mean More Compulsory Licensing?

Executive Summary

After making noise about issuing a compulsory license, Colombia is now moving to force Novartis AG to lower its price for Glivec. The news could signal that pharmaceutical companies with high-priced medicines will face increasing threats to their intellectual property if they continue to charge big prices that middle- income countries cannot afford.

You may also be interested in...

Colombian Crack Down On Compulsory Licensing Under Attack

Civil society groups are calling for Colombian authorities to repeal a controversial decree that they say will make compulsory licensing harder and which would prevent declarations of public interest from being used to lower drug prices.

Novartis Takes On Colombia Over Glivec Pricing

Novartis is taking Colombian authorities to court over moves to cut the price of its anticancer Glivec (imatinib) and warns that the intellectual property rights of other products are under threat. Companies selling hepatitis C drugs should pay attention as their products could be next to face similar measures.

Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts